Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 0.58 |
| ▸ | CA2 | P00918 | 13/20 | 0.58 |
| ▸ | CA12 | O43570 | 6/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.58 |
| ▸ | CA9 | Q16790 | 10/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 3/20 | 0.35 |
| ▸ | CA3 | P07451 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392284 | 0.91 | CA2 (0.54) | CA1CA2CA12CA14CA9 | |
| SCHEMBL293306 | 0.90 | CA1 (0.71) | CA1CA2CA12CA14CA9 | |
| Methane SCHEMBL8657931 | 0.88 | CA1 (0.68) | CA1CA2CA12CA14CA9 | |
| SCHEMBL25129256 | 0.86 | CA2 (0.65) | CA1CA2CA12CA14CA9 | |
| SCHEMBL293342 | 0.86 | CA1 (0.81) | CA1CA2CA12CA14CA9 | |
| SCHEMBL293003 | 0.85 | CA1 (0.80) | CA1CA2CA12CA14CA9 | |
| SCHEMBL293336 | 0.83 | CA2 (0.68) | CA1CA2CA12CA14CA9 | |
| SCHEMBL24248274 | 0.82 | CA1 (0.60) | CA1CA2CA12CA14CA9 | |
| SCHEMBL15546426 | 0.81 | CA2 (0.65) | CA1CA2CA12CA14CA9 | |
| SCHEMBL23319282 | 0.81 | CA2 (0.65) | CA1CA2CA12CA14CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158790-B2 | Cyclic amine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2036896-B1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2036896-A1 | CYCLIC AMINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | HRH3, HRH4, H1-0 | CA1 4685/4885CA2 2321/4885CA12 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.